<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre=": bold;} span.year {font-family : courier ; font-style : italic;}" exact="Kidney" post="Int RepKidney Int RepKidney International Reports2468-0249Elsevier pmcid: 7128395S2468-0249(20)31170-0 doi:"/>
 <result pre="10.1016/j.ekir.2020.04.001 : Review Management of Patients on Dialysis and With" exact="Kidney" post="Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy"/>
 <result pre="in Brescia, Italy AlbericiFedericofederico.alberici@unibs.it12∗DelbarbaElisa2ManentiChiara2EconimoLaura2ValerioFrancesca2PolaAlessandra2MaffeiCamilla2PossentiStefano2PivaSimone13LatronicoNicola13FocàEmanuele45CastelliFrancesco45GaggiaPaola2MovilliEzio2BoveSergio6MalbertiFabio7FarinaMarco8BracchiMartina9CostantinoEster Maria10BossiniNicola2GaggiottiMario2ScolariFrancesco12on behalf of the collab: Brescia" exact="Renal" post="COVID Task Force11AlbericiFedericoDelbarbaElisaManentiChiaraEconimoLauraValerioFrancescaPolaAlessandraMaffeiCamillaPossentiStefanoZambettiNicoleVenturiniMargheritaAffatatoStefaniaPiarulliPaolaZappaMattiaGueriniAliceBoniFrancescaMucchettiAlbertoPezziniElenaSaccàChiaraMoscatoMariannaTonoliMichelaPasqualiStefanoViolaFabioPivaSimoneLatronicoNicolaFocàEmanueleQuiros-RoldanEugeniaCastelliFrancescoGaggiaPaolaMovilliEzioBoveSergioMalbertiFabioFarinaMarcoBracchiMartinaCostantinoEster MariaBossiniNicolaGaggiottiMarioScolariFrancesco[1], [2], [3], [4], [5], [6],"/>
 <result pre="Brescia, Italy AlbericiFedericofederico.alberici@unibs.it12∗DelbarbaElisa2ManentiChiara2EconimoLaura2ValerioFrancesca2PolaAlessandra2MaffeiCamilla2PossentiStefano2PivaSimone13LatronicoNicola13FocàEmanuele45CastelliFrancesco45GaggiaPaola2MovilliEzio2BoveSergio6MalbertiFabio7FarinaMarco8BracchiMartina9CostantinoEster Maria10BossiniNicola2GaggiottiMario2ScolariFrancesco12on behalf of the collab: Brescia Renal" exact="COVID" post="Task Force11AlbericiFedericoDelbarbaElisaManentiChiaraEconimoLauraValerioFrancescaPolaAlessandraMaffeiCamillaPossentiStefanoZambettiNicoleVenturiniMargheritaAffatatoStefaniaPiarulliPaolaZappaMattiaGueriniAliceBoniFrancescaMucchettiAlbertoPezziniElenaSaccàChiaraMoscatoMariannaTonoliMichelaPasqualiStefanoViolaFabioPivaSimoneLatronicoNicolaFocàEmanueleQuiros-RoldanEugeniaCastelliFrancescoGaggiaPaolaMovilliEzioBoveSergioMalbertiFabioFarinaMarcoBracchiMartinaCostantinoEster MariaBossiniNicolaGaggiottiMarioScolariFrancesco[1], [2], [3], [4], [5], [6], [7],"/>
 <result pre="Civili 1, 25125 Brescia, Italy. federico.alberici@unibs.it 11Members of the Brescia" exact="Renal" post="COVID Task Force are listed in the Appendix. pmc-release:"/>
 <result pre="1, 25125 Brescia, Italy. federico.alberici@unibs.it 11Members of the Brescia Renal" exact="COVID" post="Task Force are listed in the Appendix. pmc-release: 2020-4-4collection:"/>
 <result pre="article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract The severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus"/>
 <result pre="under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract The severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease"/>
 <result pre="the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Abstract The severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), also known as coronavirus disease (COVID-19),"/>
 <result pre="severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as" exact="coronavirus disease" post="(COVID-19), is a major pandemic challenging health care systems"/>
 <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus" exact="disease" post="(COVID-19), is a major pandemic challenging health care systems"/>
 <result pre="although the consensus is moving toward the need of a" exact="biphasic" post="approach. During the first phase of the disease (from"/>
 <result pre="of a biphasic approach. During the first phase of the" exact="disease" post="(from onset of the symptoms up to 7–10 days)"/>
 <result pre="occasionally signs of the hemophagocytic syndrome. The management of the" exact="disease" post="in patients with kidney disease is even more challenging,"/>
 <result pre="hemophagocytic syndrome. The management of the disease in patients with" exact="kidney disease" post="is even more challenging, especially in those who are"/>
 <result pre="syndrome. The management of the disease in patients with kidney" exact="disease" post="is even more challenging, especially in those who are"/>
 <result pre="of our cohort, to better clarify the pathogenesis of the" exact="disease" post="and clinical management. Key Words COVID-19 dialysis kidneys management"/>
 <result pre="SARS-CoV-2 transplant We describe our experience with managing patients with" exact="kidney disease" post="during the current COVID-19 pandemic in Brescia City in"/>
 <result pre="transplant We describe our experience with managing patients with kidney" exact="disease" post="during the current COVID-19 pandemic in Brescia City in"/>
 <result pre="dialysis and patients with renal transplantation. The Chinese Center for" exact="Disease" post="Control and Prevention recently published the largest COVID-19 case"/>
 <result pre="age group), the main risk factors are the presence of" exact="cardiovascular" post="diseases (10.5% mortality), diabetes (7.3% mortality), chronic respiratory diseases"/>
 <result pre="risk factors are the presence of cardiovascular diseases (10.5% mortality)," exact="diabetes" post="(7.3% mortality), chronic respiratory diseases (6.3% mortality), high blood"/>
 <result pre="the presence of cardiovascular diseases (10.5% mortality), diabetes (7.3% mortality)," exact="chronic" post="respiratory diseases (6.3% mortality), high blood pressure (6% mortality),"/>
 <result pre="presence of cardiovascular diseases (10.5% mortality), diabetes (7.3% mortality), chronic" exact="respiratory" post="diseases (6.3% mortality), high blood pressure (6% mortality), and"/>
 <result pre="(10.5% mortality), diabetes (7.3% mortality), chronic respiratory diseases (6.3% mortality)," exact="high blood pressure" post="(6% mortality), and cancer (5.6% mortality).1,2 In the Lombardy"/>
 <result pre="respiratory diseases (6.3% mortality), high blood pressure (6% mortality), and" exact="cancer" post="(5.6% mortality).1,2 In the Lombardy region, however, the disease"/>
 <result pre="and cancer (5.6% mortality).1,2 In the Lombardy region, however, the" exact="disease" post="seems to have much higher mortality rates than reported"/>
 <result pre="with increased mortality during COVID-19 are common in patients with" exact="chronic" post="kidney disease (CKD) and in patients undergoing renal replacement"/>
 <result pre="increased mortality during COVID-19 are common in patients with chronic" exact="kidney disease" post="(CKD) and in patients undergoing renal replacement therapy with"/>
 <result pre="mortality during COVID-19 are common in patients with chronic kidney" exact="disease" post="(CKD) and in patients undergoing renal replacement therapy with"/>
 <result pre="data on the risk factors and outcome of patients with" exact="kidney disease" post="who are positive for COVID-19, including those receiving dialysis"/>
 <result pre="on the risk factors and outcome of patients with kidney" exact="disease" post="who are positive for COVID-19, including those receiving dialysis"/>
 <result pre="Reports from China suggest a less severe course of the" exact="disease" post="in patients receiving dialysis, compared with patients who underwent"/>
 <result pre="underwent a kidney transplantation, but also compared with patients without" exact="kidney disease." post="Currently, Brescia and its province are the second largest"/>
 <result pre="as of March 23, 2020). A working group consisting of" exact="infective" post="disease specialists and intensivists from Lombardy has developed a"/>
 <result pre="of March 23, 2020). A working group consisting of infective" exact="disease" post="specialists and intensivists from Lombardy has developed a therapeutic"/>
 <result pre="developed a therapeutic protocol in patients with COVID-19 based on" exact="disease" post="severity.4 We have adapted this protocol to our patients"/>
 <result pre="The management of these patients makes it necessary to reconcile" exact="infection" post="protocols (e.g., isolation), with needs that are intrinsic to"/>
 <result pre="nephrology ward compared with the patients managed in other general" exact="COVID" post="areas, and evaluated by the nephrologist only in consultation."/>
 <result pre="wards to accommodate the surge of patients with COVID-19 with" exact="kidney disease." post="The particular logistics of our institution has allowed us"/>
 <result pre="efficient organizational model that included the creation of a dedicated" exact="COVID" post="unit from a female ward. From February 27–28, 2020,"/>
 <result pre="included the creation of a dedicated COVID unit from a" exact="female" post="ward. From February 27–28, 2020, we created a dedicated"/>
 <result pre="female ward. From February 27–28, 2020, we created a dedicated" exact="COVID" post="unit that was dialysis capable and subsequently admitted the"/>
 <result pre="we admitted the second and third positive patients to the" exact="COVID" post="area. As the number of patients infected with COVID-19"/>
 <result pre="to create hemodialysis rooms, intended partially for patients with SARS-CoV-2" exact="infection" post="and partially for patients who are negative for SARS-CoV-2"/>
 <result pre="Table 1 Number of patients at the peak of the" exact="COVID" post="pandemic 1st Floor Inpatients with COVID-19 infection receiving hemodialysis17"/>
 <result pre="peak of the COVID pandemic 1st Floor Inpatients with COVID-19" exact="infection" post="receiving hemodialysis17 beds Hemodialysis room for inpatients with COVID-19"/>
 <result pre="infection receiving hemodialysis17 beds Hemodialysis room for inpatients with COVID-19" exact="infection" post="Hemodialysis rooms for inpatients who are negative for COVID-19"/>
 <result pre="are negative for COVID-19 Dialysis room for inpatients with COVID-19" exact="infection" post="or suspected cases Inpatients with COVID-19 who received transplantation12"/>
 <result pre="received transplantation12 beds 2nd Floor Dialysis COVID-negative nephrology ward COVID," exact="coronavirus disease." post="Patient Flow Logistical challenges and the physical structure of"/>
 <result pre="patients receiving hemodialysis, and 5 patients affected by CKD or" exact="acute" post="kidney injury on CKD. The vast majority of patients"/>
 <result pre="receiving hemodialysis, and 5 patients affected by CKD or acute" exact="kidney injury" post="on CKD. The vast majority of patients (19 of"/>
 <result pre="CKD. To date, no patients on immunosuppressive treatment due to" exact="primary" post="or secondary glomerulonephritis have been admitted or known to"/>
 <result pre="date, no patients on immunosuppressive treatment due to primary or" exact="secondary" post="glomerulonephritis have been admitted or known to have symptoms"/>
 <result pre="no patients on immunosuppressive treatment due to primary or secondary" exact="glomerulonephritis" post="have been admitted or known to have symptoms imputable"/>
 <result pre="average of 13 days. We admitted 21 patients with COVID-19" exact="infection" post="receiving hemodialysis, including 5 patients who died and 4"/>
 <result pre="at some stages, rationalization of intensive care unit resources. A" exact="total" post="of 5 patients with CKD were admitted, of whom"/>
 <result pre="17 days from admission. Management Considerations In general terms, optimal" exact="disease" post="management is still being debated, and the therapeutic approach"/>
 <result pre="to the same family of Betacoronaviruses (SARS and Middle East" exact="respiratory" post="syndrome), the current COVID-19 pandemic requires the identification of"/>
 <result pre="transplant patients in particular.6 The pharmacological approach to treating SARS-CoV-2" exact="infection" post="can be viewed as a 2-phase approach. The first"/>
 <result pre="as a 2-phase approach. The first phase is associated with" exact="viral" post="replication and cytopathic effect, and antiviral drugs may be"/>
 <result pre="lopinavir/ritonavir, darunavir ritonavir, and darunavir/cobicistat). The second phase of the" exact="disease" post="begins after 7 to 10 days from the onset"/>
 <result pre="of oxygen supplementation and ventilatory support, which seems to be" exact="secondary" post="to hyperinflammatory and cytokine release syndromes. Immunosuppressive and immunomodulatory"/>
 <result pre="role of antiviral activity of chloroquine toward the SARS and" exact="avian influenza" post="viruses in in vitro and animal models.7,8 Clinical evidence"/>
 <result pre="and animal models.7,8 Clinical evidence to support their use remains" exact="limited" post="at this time.9 Because of similar molecular structure, a"/>
 <result pre="showing benefit with lopinavir/ritonavir treatment beyond standard care in hospitalized" exact="adult" post="patients with severe COVID-19,13 but these results are limited"/>
 <result pre="hospitalized adult patients with severe COVID-19,13 but these results are" exact="limited" post="and, in our opinion, not conclusive. For example, baseline"/>
 <result pre="opinion, not conclusive. For example, baseline characteristics suggest a higher" exact="disease" post="severity in the treatment arm (more patients with respiratory"/>
 <result pre="higher disease severity in the treatment arm (more patients with" exact="respiratory" post="rate &amp;gt;24/min, with days from onset to randomization &amp;gt;12"/>
 <result pre="randomization &amp;gt;12 and requiring oxygen) and, interestingly, an associated higher" exact="viral" post="load. Despite that, patients treated with lopinavir/ritonavir experienced a"/>
 <result pre="has been suggested that it plays a role in reducing" exact="viral" post="load and improving lung function parameters in animal and"/>
 <result pre="cells.7 Azithromycin A small study performed on patients with COVID-19" exact="infection" post="and treated with hydroxychloroquine demonstrated that combination with azithromycin"/>
 <result pre="the one characterized by potential rapidly progressive lung involvement and" exact="secondary" post="to hyperinflammatory syndrome and cytokine release syndrome. Of note,"/>
 <result pre="by potential rapidly progressive lung involvement and secondary to hyperinflammatory" exact="syndrome" post="and cytokine release syndrome. Of note, data suggest a"/>
 <result pre="significant impact on the survival curves of patients with COVID-19" exact="infection" post="who have developed acute respiratory distress syndrome.16 Tocilizumab In"/>
 <result pre="survival curves of patients with COVID-19 infection who have developed" exact="acute" post="respiratory distress syndrome.16 Tocilizumab In consideration of the central"/>
 <result pre="curves of patients with COVID-19 infection who have developed acute" exact="respiratory" post="distress syndrome.16 Tocilizumab In consideration of the central role"/>
 <result pre="a role in the management of selected cases in the" exact="absence of" post="major contraindications. Clinical Patient Management and Monitoring Patients with"/>
 <result pre="contraindications. Clinical Patient Management and Monitoring Patients with known COVID-19" exact="infection" post="receive a chest X-ray at baseline and repeated when"/>
 <result pre="Management and Monitoring Patients with known COVID-19 infection receive a" exact="chest" post="X-ray at baseline and repeated when respiratory deterioration is"/>
 <result pre="infection receive a chest X-ray at baseline and repeated when" exact="respiratory" post="deterioration is noted. Even patients who are afebrile may"/>
 <result pre="noted. Even patients who are afebrile may have an abnormal" exact="chest" post="X-ray and other clinical signs of the hemophagocytic syndrome."/>
 <result pre="of the blood tests including ferritin–coagulation–liver enzymes, and of the" exact="chest" post="X-ray. We have formulated a treatment protocol based on"/>
 <result pre="treatment protocol based on patient characteristics, phase of illness, and" exact="disease" post="severity using antivirals, immunomodulators, and immunosuppressive agents. These protocols"/>
 <result pre="patients receiving hemodialysis and who underwent transplantation with a SARS-CoV-2" exact="infection" post="can be found in the Supplementary Appendix S1. We"/>
 <result pre="in the Supplementary Appendix S2. Appendix Members of The Brescia" exact="Renal" post="COVID Task Force Federico Alberici, Department of Medical and"/>
 <result pre="the Supplementary Appendix S2. Appendix Members of The Brescia Renal" exact="COVID" post="Task Force Federico Alberici, Department of Medical and Surgical"/>
 <result pre="Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; and" exact="Infectious" post="and Tropical Diseases, Spedali Civili Hospital, ASST Spedali Civili"/>
 <result pre="Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; and" exact="Infectious" post="and Tropical Diseases, Spedali Civili Hospital, ASST Spedali Civili"/>
 <result pre="Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; and" exact="Infectious" post="and Tropical Diseases, Spedali Civili Hospital, ASST Spedali Civili"/>
 <result pre="Material Supplementary File (PDF) LINK References References 1The Novel Coronavirus" exact="Pneumonia" post="Emergency Response Epidemiology Team. Vital Surveillances: The Epidemiological Characteristics"/>
 <result pre="The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus" exact="Disease" post="(COVID-19)—Chinese, 2020. Available at: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51. Accessed March 22, 2020."/>
 <result pre="March 22, 2020 5World Health Organization. Clinical management of severe" exact="acute" post="respiratory infection when COVID-19 is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected."/>
 <result pre="22, 2020 5World Health Organization. Clinical management of severe acute" exact="respiratory" post="infection when COVID-19 is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed"/>
 <result pre="2020 5World Health Organization. Clinical management of severe acute respiratory" exact="infection" post="when COVID-19 is suspected. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed March"/>
 <result pre="S, et al. The novel Coronavirus 2019 pandemic and kidneys." exact="Kidney" post="Int, in press. 7WangM.CaoR.ZhangL.Remdesivir and chloroquine effectively inhibit the"/>
 <result pre="23, 2020. 10van den BorneB.E.DijkmansB.A.de RooijH.H.Chloroquine and hydroxychloroquine equally affect" exact="tumor" post="necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral"/>
 <result pre="affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by" exact="peripheral" post="blood mononuclear cellsJ Rheumatol24199755609002011 11Zhou D, Dai SM, Tong"/>
 <result pre="a recommendation to examine the effect of hydroxychloroquine in preventing" exact="infection" post="and progression [e-pub ahead of print]. J Antimicrob Chemother."/>
 <result pre="Chen X, Cai Y, et al. Risk factors associated with" exact="acute respiratory distress syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="X, Cai Y, et al. Risk factors associated with acute" exact="respiratory" post="distress syndrome and death in patients with coronavirus disease"/>
 <result pre="Y, et al. Risk factors associated with acute respiratory distress" exact="syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="with acute respiratory distress syndrome and death in patients with" exact="coronavirus disease" post="2019 pneumonia in Wuhan, China [e-pub ahead of print]."/>
 <result pre="acute respiratory distress syndrome and death in patients with coronavirus" exact="disease" post="2019 pneumonia in Wuhan, China [e-pub ahead of print]."/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, China [e-pub ahead of print]. JAMA Intern"/>
 <result pre="JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.0994. Accessed March 22, 2020. 17FreyN.PorterD.Cytokine release" exact="syndrome" post="with chimeric antigen receptor T cell therapyBiol Blood Marrow"/>
 <result pre="17FreyN.PorterD.Cytokine release syndrome with chimeric antigen receptor T cell therapyBiol" exact="Blood" post="Marrow Transplant252019e123e12730586620 Supplementary File (PDF) Appendix S1. Proposal for"/>
</results>
